Merck Acquires Terns Pharmaceuticals, Enhancing Oncology Pipeline with TERN-701
Merck has completed the acquisition of Terns Pharmaceuticals, gaining TERN-701, a novel BCR::ABL1 inhibitor.
Asset / Drug
Drug and asset intelligence for TERN-701 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.